Background. Tenofovir (TDF) is effective for treatment of hepatitis B virus (HBV) in human immunodeficiency virus (HIV) infection; however, some individuals have ongoing HBV viremia, the reasons for which are unclear. We determined the patterns and factors associated with detectable HBV DNA in HIV-HBV-coinfected subjects on highly active antiretroviral therapy (HAART).
Tenofovir disoproxil fumarate (TDF) was approved for the treatment of human immunodeficiency virus (HIV) in 2001 and is currently one of the most widely prescribed, potent, and well-tolerated antiretroviral agents. Because of its dual activity against HIV and hepatitis B virus (HBV), it has been of particular benefit for individuals with HIV-HBV coinfection. In this group, it effectively suppresses both wild-type and lamivudine-resistant HBV and reverses the parameters of advanced liver disease [1] [2] [3] [4] .
Recently, 2 European cohorts reported high rates of HBV suppression maintained between 3 and 5 years in those treated with TDF [5, 6] . In the first study, 10 participants failed to achieve a virologic response and 4 experienced virologic breakthrough without evidence of TDF resistance mutations [6] . In the second study, undetectable HBV DNA was achieved in 89% of participants [5] . Eight participants had persistent viremia, including 3 demonstrating a significant reduction from baseline without full suppression again without evidence of drug resistance.
Therefore, it is clear that although TDF is highly effective in the majority, some patients experience a suboptimal responseeither in a persistently viremic pattern or as virologic breakthrough without resistance. Although obvious inadequate adherence explains some of these cases, the observation that HIV RNA remains suppressed in many such cases argues against this. In 2008, we reported our cross-sectional findings that at entry to an international cohort study of HIV-HBVcoinfected individuals, TDF combination therapy was more strongly associated with HBV DNA suppression than was TDF (or LAM) monotherapy [7] . The purpose of this study was to determine longitudinal outcomes from the same cohort with up to 3.9 years of follow-up including an in-depth analysis of the patterns and factors associated with suboptimal responses to TDF-based therapy. [7] . Subjects were included if they had HIV infection, determined by the presence of HIV antibody; hepatitis B surface antigen (HBsAg) positive on 2 occasions separated by a minimum of 6 months, with at least 1 of these occasions prior to initiation of highly active antiretroviral therapy (HAART); were on HAART at enrollment or expected to start HAART within 1 year of enrollment; and had a known date of HAART initiation. Individuals coinfected with chronic hepatitis C virus or hepatitis delta were ineligible. All subjects were followed semiannually for the study duration. Written informed consent was obtained from all participants, and the study was approved by the relevant Human Research Ethics Committees in Australia, the United States, and Thailand.
METHODS

Study Participants and Data Collection
For inclusion in this analysis, all subjects had to have commenced HAART and had HBV DNA available for assessment. Consequently, 4 subjects who did not start HAART by their last study visit or had no HBV DNA data were excluded. Subjects who had previous documentation of HBsAg positivity but who had lost HBsAg during follow-up were included. Clinical and laboratory data were collected from medical records at every visit. For those who had initiated HAART prior to study enrollment, these data were abstracted from their date of HAART initiation. Adherence was assessed by standardized self-report.
Laboratory Testing
HBV DNA was extracted from serum stored at −80°C and quantified by the respective site laboratories using a real-time HBV DNA assay (RealART HBV LC PCR [Qiagen] , COBAS Amplicor HBV [Roche], Abbott RealTime HBV DNA [Abbott Molecular], or Versant HBV DNA 3.0 [Bayer Diagnostics]). The lower limit of detection (LLOD) for these assays ranged from 6 IU/mL to 357 IU/mL. Although only 2.4% of tests were performed using the assay with an LLOD of 357 IU/mL, this value was used as the cutoff for undetectable HBV DNA for the primary analyses because it was the lowest common threshold across all 3 assays. Because the majority (94%) of tests were performed using assays with an LLOD of ≤20 IU/ mL, sensitivity analyses were performed using only data from these more sensitive assays. HIV RNA was quantified by commercially available approved real-time polymerase chain reaction tests, performed according to the manufacturer's instructions. The LLOD for these assays ranged from 50 copies/mL to 400 copies/mL, and we considered 400 copies/ mL as undetectable as the lowest common threshold. However, for the final multivariate analysis we also considered <50 copies/mL as indicative of optimal HIV control.
Statistical Methods
This longitudinal study included data from up to 11 visits for each participant. Only study visits at which participants were taking HAART were included in these analyses. For all primary analyses, detectable HBV DNA was defined as HBV DNA >357 IU/mL. An additional 123 (12.1%) HBsAg-negative person-visits were classified as undetectable HBV DNA. We conducted this person-visit analysis using multiple logistic regression models with robust variance estimation [8] to determine which characteristics were independently associated with detectable HBV DNA while accounting for within-subject correlations across repeated visits. Covariates for study visit and study site were included in all models to account for the prospective study design and the fundamental differences between the cohorts. Initially, we fit 3 preliminary models focusing separately on demographic and behavior variables, HBV-related variables, and HIV-related variables, and then constructed a comprehensive multiple regression model from the covariates forced into all models plus those that had adjusted P values <.20 in the preliminary models. The final model included study visit, site, age, and the covariates that were independently associated with detectable HBV DNA in the preliminary models. All associations were quantified using odds ratios (ORs) and 95% confidence intervals (CIs). Multiple imputation was used to account for missing data in the regression analyses [9] . All statistical analyses were performed using SAS software, version 9.22 (SAS Institute, Cary, North Carolina), and statistical significance was defined as a 2-sided P value <.05.
RESULTS
Study Population and Baseline Characteristics
The study population of 165 HIV-HBV-coinfected participants were followed from their earliest eligible study visit (baseline) for a median of 2.8 years (interquartile range [IQR], 2.0-3.9 years), yielding a total of 1015 study visits. At baseline, the median duration of HAART was 3.5 years with the majority (89%) on an HBV-active regimen. Baseline demographic characteristics are summarized in Table 1 .
The most common HBV-active component in the HAART regimen was TDF in conjunction with either lamivudine (LMV) or emtricitabine (FTC) (57% of participants). LMV or FTC monotherapy was prescribed for 19%, and 13% received TDF monotherapy. For participants on TDF (with or without FTC or LMV), the median duration of TDF by end of study follow-up was 4.2 years (IQR, 2.9-5.4 years).
At baseline, 49% of the cohort was hepatitis B e antigen (HBeAg) positive (34% Thai, 55% Australian, and 56% MACS) and HBV DNA was detectable in 29% of participants. When stratified by HBeAg status, 50% of HBeAg-positive and 9% of HBeAg-negative individuals had detectable HBV DNA. The proportion of participants with detectable HBV DNA was highest in the United States (47%), followed by Australia (31%) and Thailand (6%). , detectable HIV RNA, and <95% adherence to HAART regimen (Table 2 ). In particular, participants receiving TDF plus FTC or LMV had the highest proportion with undetectable HBV DNA (86.3%) across all study visits (Figure 1) Since most HBV DNA testing in clinical practice is based on assays with more sensitive LLOD, a secondary analysis was performed including only visits where the HBV DNA assay LLOD was ≤20 IU/mL (Supplementary Table 1 ). In this sensitivity analysis, the number of visits with detectable HBV DNA increased from 21% to 38%, indicating that very low-level viremia (20-357 IU/mL) was relatively frequent. Furthermore, only HBeAg positivity, HAART <2 years, detectable HIV RNA, and HBV-active ARV regimen (LAM/FTC monotherapy and not taking HBV-active drug) remained statistically significant.
Predictors of Detectable HBV DNA in Subjects on TDF-Based HAART
Since TDF is the recommended agent in HIV-HBV-coinfection, we determined factors associated with detectable HBV DNA among the subgroup of subjects on TDF-based HAART. We examined 3 different scenarios: (1) all subjects on TDFbased HAART, (2) only those taking TDF-based HAART for ≥6 months, and (3) To determine factors associated with detectable HBV DNA in participants with optimal HIV control, we fit additional models including only those with undetectable HIV RNA. For this analysis, we ran the model using both an HIV RNA <400 copies/mL (lowest common threshold) and an HIV RNA <50 copies/mL (excluding patients with HIV RNA values between 50 copies/mL and 400 copies/mL). No difference was seen between the models with regard to the factors associated with detectable HBV DNA. In the strictest scenario (HIV RNA <50 copies/mL) and where the model was further restricted to participants on TDF + FTC/LAM, HBeAg positivity ( Table 3) .
Patterns of HBV Nonresponse in Participants Receiving TDF-Based HAART
In 138 participants treated with TDF, 62 had a suboptimal response, which fell into 1 of 3 typical patterns. The first includes 25 participants (18%) who failed to achieve any undetectable HBV DNA (<357 IU/mL) despite having received at least 12 months of TDF-based HAART ( persistent viremic group). Although HBV DNA was declining slowly but continuously in a few of these cases, the majority were persistently viremic with levels varying up to 3 log IU/mL and often with a similarly fluctuating HIV RNA level (Figure 2A ). The second pattern includes 13 participants (9%) who experienced viral rebound of >1 log IU/mL from nadir while on TDF (viral rebound group). All but 1 of these patients were HBV undetectable (<357 IU/mL) before rebound. HIV RNA also became detectable in the majority of these cases suggesting nonadherence or therapy interruption ( Figure 2B ). Of note, potential TDF resistance mutations were not detected in this viral rebound group. Those with rebound who maintained an undetectable HIV RNA had HBV DNA rebounds that were generally low (1.1-3.7 log IU/mL). The third pattern of suboptimal response was achieving an undetectable HBV DNA but then experiencing intermittent low levels of HBV DNA (<1 log IU/mL increase), usually followed by a return to undetectable levels (viral blip group). This pattern of response occurred in 24 (17%) of participants and was rarely associated with loss of HIV control ( Figure 2C) .
DISCUSSION
This longitudinal analysis of a large, multinational, prospective cohort of HIV-HBV-coinfected individuals, with the majority on HBV-active HAART, confirms our prior cross-sectional findings [7] that therapy with TDF plus FTC or LMV is indeed superior to TDF monotherapy. This finding was demonstrated in the entire cohort and also when the analysis was restricted to those taking a TDF-based HAART regimen. This study also finds that CD4 cell counts <200 cells/mm 3 , HBeAg positivity, <2 years of HAART, and <95% compliance with HAART regimen are associated with detectable HBV DNA in those with undetectable HIV RNA while on TDF-based HAART. Last, this study defines patterns of HBV viremia for subjects on TDF-based HAART who had detectable HBV DNA. Because this cohort was LMV-experienced at study entry, this study does not address whether the combination of TDF with FTC or LMV would be more efficacious than TDF monotherapy in treatment-naive HIV-HBV-coinfected subjects. The only study in treatment-naive subjects did not show a significant benefit for combination therapy, but only followed patients for 48 weeks [10] .
Although TDF is a highly potent and successful agent for both HIV and HBV, a proportion of individuals do not achieve HBV DNA suppression. In studies to date, failure to achieve an undetectable HBV DNA (<10-20 IU/mL) has been reported in 11%-12% of individuals [5, 6] . The reasons for nonsuppression are ill defined and not clearly related to HBV resistance, which has rarely been reported in the context of TDF [11, 12] , and did not occur in our participants. In our prospectively followed TDF-treated participants, a much higher proportion (44%) were shown to have a suboptimal (ie, were not persistently undetectable) response to TDF characterized by 1 of 3 responses-persistent viremia, viral rebound, or viral blip. Two likely reasons for our higher rate of suboptimal responses are the inclusion of the latter 2 definitions, especially of those with viral blip, and the assessment of prospective viral profiles rather than in a cross-sectional manner at last follow-up. The viral blip category is interesting because those participants had an undetectable HIV RNA and low levels of HBV DNA on rebound. Whether these blips represent ongoing replication or release of virions from the hepatic reservoir requires further study. In HIV-infected individuals on treatment, it has been shown that blips in HIV RNA likely represent release from reservoirs and not replication [13, 14] .
In the multivariable analysis restricted to those on combination therapy and with undetectable HIV RNA, it is not surprising that HBeAg positivity is associated with detectable HBV DNA, because HBV DNA is higher in untreated participants who are HBeAg positive. The association of lower CD4 counts with detectable HBV DNA is intriguing because it suggests that the degree of immunosuppression affects the ability to respond to anti-HBV therapy. Although the mechanism for this association is not clear, one explanation is that a contribution from the immune system is important in achieving an undetectable HBV DNA during therapy. These data support recommendations for early initiation of HAART in HIV-HBV-coinfected participants. Further studies are needed to determine whether there is a difference in response to anti-HBV therapy at higher CD4 counts of 350 or 500 cells/mm 3 . One of the most fascinating findings is that among subjects with excellent adherence in terms of having undetectable HIV RNA, those with <95% adherence were more likely to have detectable HBV DNA, which has not been previously documented. Because replication rates of HBV are greater than HIV, it is reasonable that a higher level of compliance is needed to have a persistently undetectable HBV DNA. The consequences for these blips and rebounds that may be due to <95% adherence are unknown; thus, further study of such individuals is warranted. However, it is important to note that the majority of subjects who had been taking a TDF-based regimen for a median of 4 years had maintained an undetectable HBV DNA level during this period. Together with 2 other cohorts that reported high HBV DNA suppression rates over a similar follow-up period [5, 6] , our findings demonstrate that TDF is an effective long-term anti-HBV agent in HIV-HBV coinfection.
This study has several strengths including the large number of HIV-HBV coinfected subjects on TDF for an extended period, the inclusion of subjects who received TDF monotherapy as well as TDF with FTC/LMV, and the prospective follow-up allowing determination of patterns of detectable HBV DNA. The study is limited by the fact that we did not follow all subjects since TDF initiation and, thus, do not have HBV DNA levels pretherapy which could aid in our understanding of the HBV DNA patterns we observed. Second, few patients in the cohort underwent liver biopsy and none had Fibroscan recorded; thus, any association between level of hepatic fibrosis and HBV replication could not be explored. Third, we are not aware of why a particular HBV-active HAART regimen was chosen for each subject, so we could not account for this in our analysis. Last, a range of different HBV DNA assays were performed over the duration of the cohort; however, the sensitivity analysis with 20 IU/mL as the LLOD demonstrated that most of the associations remained, with the major exception being the <95% adherence covariate. This suggests that, unlike with higher levels of HBV DNA, suboptimal adherence is not associated with episodes of low-level viremia between 20 IU/mL and 357 IU/mL, which would support the theory (as in HIV) that very low-level HBV viremia is possibly driven by other mechanisms, such as release from viral reservoirs, and may not be clinically significant. Further work is needed to confirm this hypothesis.
In summary, this study demonstrates that in HIV-HBVcoinfected subjects with prior LMV experience, combination therapy with TDF and FTC/LMV increases the likelihood for sustained HBV DNA suppression. In addition, we identified several patterns of HBV DNA in individuals who are not suppressed and demonstrated that more advanced immunodeficiency and suboptimal compliance with the anti-HBV regimen decreases the likelihood of a sustained response in HIV-HBV-coinfected subjects on TDF with FTC or LMV. Emphasizing the importance of full adherence to maintain both HIV and HBV control is critical in HIV-HBV-coinfected individuals.
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